NASA moon orbiter spies grave of crashed Japanese lunar lander (image)
When you buy through links on our articles, Future and its syndication partners may earn a commission.
NASA's Lunar Reconnaissance Orbiter (LRO) has imaged the crash site of Resilience, a moon lander built and operated by the Tokyo-based company ispace.
Resilience tried to touch down on June 5 in the center of Mare Frigoris (Sea of Cold), a volcanic region interspersed with large-scale faults known as wrinkle ridges.
Mare Frigoris formed over 3.5 billion years ago as massive basalt eruptions flooded low-lying terrain, according to Mark Robinson, a lunar scientist for the company Intuitive Machines who is based in Phoenix, Arizona. Later, the wrinkle ridges formed as the crust buckled under the weight of the heavy basalt deposits.
Shortly after Resilience's landing sequence, the ispace Mission Control Center was unable to establish communications with the spacecraft. The team determined that Resilience had likely been lost, a conclusion that was firmed up a few hours later.
Also lost on landing was the Tenacious microrover, a small wheeled vehicle developed in Luxembourg by ispace's European subsidiary. Tenacious carried a piece of artwork on its front bumper — Mikael Genberg's "Moonhouse," a small replica of the red-and-white homes famous in Sweden.
Related stories:
— Private Japanese spacecraft crashes into moon in 'hard landing,' ispace says
— Japan's Resilience moon lander aces lunar flyby ahead of historic touchdown try (photo)
— Japan's Resilience moon lander arrives in lunar orbit ahead of June 5 touchdown
Resilience left some telltale marks when it slammed into the moon on June 5, and LRO noticed them.
"The dark smudge formed as the vehicle excavated and redistributed shallow regolith (soil); the faint bright halo resulted from low-angle regolith particles scouring the delicate surface," Robinson, the principal investigator for the Lunar Reconnaissance Orbiter Camera, told Inside Outer Space.
The crash spot is roughly 1.5 miles (2.4 kilometers) from the landing site that ispace mapped out, to one decimal place, on its webpage. One decimal place in lunar latitude and longitude equals 19 miles (30 km), Robinson said.
Resilience was ispace's second moon lander. The company's first such probe also crashed during its touchdown try, in April 2023.
Scott Manley has more details on the Resilience crash; check out his video here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Archaeologists Recreate Prehistoric Tools to Build a Canoe for 140-Mile Ocean Voyage
More than 30,000 years ago, seafaring humans made a momentous trek from present-day Taiwan to the Ryukyu Islands of southwestern Japan—a journey of some 140 miles without any of the advanced technology that guides us today. Though Paleolithic sites on these islands contain remnants of human life from that era—including stone tools, fishhooks and hearths—they give very few clues to the boat technology of the time, likely because it relied heavily on quick-to-decay organic matter. For a new study, published on Wednesday in Science Advances, researchers reenacted that treacherous journey over three days on a boat constructed with stone tools from the period. 'Before our project, no one had seriously considered how this maritime migration occurred,' says the study's lead author Yousuke Kaifu, an anthropologist at the University of Tokyo. Years ago Kaifu gathered a team of researchers to test out possible boat designs early modern humans could have used. The team first tested reed-bundle rafts and bamboo rafts, but the vessels were too slow and were easily knocked off course by the very strong currents of the area. So the researchers next decided to try a simple canoe like those known to have been used in the area about 10,000 years ago. They chopped down a three-foot-thick Japanese cedar tree using stone axes with wooden handles, dug out the inside and shaped it into a 25-foot-long canoe that became known as 'Sugime,' a nickname that incorporates the Japanese word for cedar. [Sign up for Today in Science, a free daily newsletter] In July 2019, after two weeks of waiting for calm waters, five experienced paddlers embarked on their journey without using modern navigational tools. They soon encountered choppy seas and later struggled with sleepiness and bodily discomfort. With no GPS, the team relied on the sun, stars and other indicators of its direction. Forty-five hours and 140 miles after it started, Sugime at last arrived at the closest of the Ryukyu Islands. Although the dugout canoe was the best of the team's candidate boats, it was far from perfect—it constantly took on water, which one of the paddlers had to frequently bail out. 'I would of course love to see other researchers test other watercraft for deeper understanding of how our ancestors first ventured into the sea,' Kaifu says. The reenactment helped illustrate just how skilled and coordinated the original seafarers would have needed to be to pull off such a voyage. 'I enjoyed the project throughout because there were some new discoveries almost every day,' Kaifu says. This effort has continued a global trend of experimental archaeological boat reconstructions. One group replicated a bamboo raft from more than 800,000 years ago and used it to travel between Indonesian islands. Another team reconstructed remnants of eighth-century-C.E. boats to test on the Charente River in France. 'There's also a massive resurgence of Indigenous seafaring voyaging and experimental voyaging in the Pacific, which is really interesting at the moment,' says Helen Farr, a maritime archaeologist at the University of Southampton in England and co-host of the archaeology-focused podcast Before Us, who was not involved in the study. 'Indigenous communities are reclaiming their maritime heritage through these voyaging societies.' These and other experimental archaeological projects can help illuminate parts of human migration that have been lost history. 'You suddenly see a level of skill and planning that is really hard to see in the archaeological record for this time period,' which mostly consists of fossils and stone tools, Farr says. 'So to get an insight into an activity—a temporal, spatial, specific activity like seafaring in this region—and just the little human details that you get from it, that's what is a real, real joy.'
Yahoo
2 days ago
- Yahoo
AGC Biologics Expands Cell Therapy Development Operations to Asia to Serve Growing Market Need
TOKYO, June 26, 2025--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc.'s Yokohama Technical Center, marking the latest step in the global expansion of the company's Global Cell and Gene Technologies Division. The improved geographical footprint allows AGC Biologics to better serve customers requiring autologous and allogeneic products across all markets, with cell therapy manufacturing now available in three continents (Milan, Italy – Longmont, Colorado, U.S. – Yokohama, Japan). This new site precedes the opening of a new AGC Biologics Yokohama manufacturing facility on schedule to be operational in 2027 with pre-clinical through commercial services for mammalian-based protein biologics, cell therapies, and messenger RNA. The Yokohama location will provide process transfer and manufacturing services for pre-clinical and clinical trials to serve an expanding global cell therapy market. Its core technologies include induced pluripotent stem cells, mesenchymal stem cells, hematopoietic stem cells, and CAR-T cell therapies. AGC Biologics Cell and Gene Technology Center of Excellence in Milan, with its nine product approvals by the EMA and FDA, hundreds of batches manufactured, and 30-year track record, will support and enable the successful ramp up of operation in the new Yokohama site. "In a cell and gene therapy market of high volatility and witnessing consolidation of CDMOs, AGC Biologics is among the few experiencing significant growth and success. We are now building on this success to complete the vision of having a truly global offering," said Luca Alberici, Executive Vice President of Global Cell and Gene Technologies at AGC Biologics. "Now Asian developers can benefit from having a local supply within one of the best global infrastructures on the market for cell therapy. Moreover, customers can continue to leverage the offering of viral vector central supply in our Milan facility, which supplies around a third of the ex vivo gene therapy product approved for commercialization. AGC Biologics, through its proprietary ProntoLVV and BravoAAV platforms, aims to offer viral vectors at a sustainable cost for its clients targeting less than 1,000€ per CAR-T patient." "Our team of friendly experts in Milan have a strong reputation for collaboration and working side-by-side with customers to achieve clinical, late-phase, and commercial successes," said Jun Takami, Senior Vice President and General Manager, Japan Region and Yokohama Facility. "As part of this next major phase for cell therapy in the region, our Yokohama team is ready to support partners in accelerating drug development timelines while maintaining the highest quality standards in the industry." AGC Biologics is a part of AGC Inc.'s Life Science Company. The Life Science company operates over 10 facilities worldwide focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. The AGC Inc. Yokohama Technical Center, built in 2020, is dedicated to advancing AGC Inc.'s research and development capabilities in materials science, chemical processes, and biotechnology. Please visit to learn more about AGC Biologics' global network of services for protein biologics and cell and gene therapies. About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,600 Team Members worldwide. View source version on Contacts AGC Inc. Corporate contact:info-pr@ AGC Biologics Media Contact:Kati Sillsksills@ +1 (425) 652-1182 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Corundum Convergence Institute and the University of Tokyo's International Research Center for Neurointelligence Launch Inaugural Neuroscience Entrepreneurship Workshop
Neuro-inspired Computation and Entrepreneurship Workshop Will Equip the Next Generation of Neuroscience Entrepreneurs with Foundational Tools for Startup Creation TOKYO, June 25, 2025 /PRNewswire/ -- Corundum Convergence Institute (CCI), a non-profit venture fueling groundbreaking research at the intersection of neuroscience and systems biology, today announced it has partnered with the International Research Center for Neurointelligence (IRCN) at the University of Tokyo to launch the inaugural Neuro-inspired Computation and Entrepreneurship Workshop. The workshop runs June 30–July 1 and on July 7, 2025 at the University of Tokyo. It will complement the IRCN and Chen Institute's Joint Course on Neuro-inspired Computation, which will take place July 2–5. Bridging the worlds of neuroscience innovation, artificial intelligence and entrepreneurship, the workshop will introduce participants to foundational startup concepts, emphasizing early-stage venture creation, global market insights and investment strategies. The program is tailored to equip scientists and aspiring entrepreneurs with the tools and mindset to translate bold research into real-world impact. "The Neuro-inspired Computation and Entrepreneurship Workshop presents an exciting opportunity to create an ecosystem with the potential to become a global engine for startup creation," said Shunsuke Nagao, President of Corundum Convergence Institute and CFO of Corundum Systems Biology. "CCI is committed to nurturing the next generation of entrepreneurs, guiding the process of commercializing cutting-edge research. We are delighted to partner with IRCN for this initiative which perfectly aligns with our vision and goals." Throughout the program, participants will have the opportunity to engage with leading experts presenting on topics including product-market fit, intellectual property, financing and R&D strategies. Distinguished speakers include neurotech entrepreneur, Alain Prochiantz, PhD, who will deliver a keynote session, and neurotech strategist Jojo Platt, who will introduce attendees to the spirit of entrepreneurial leadership and innovation. "This program embodies our shared vision of what neuroscience innovation can become when disciplines, generations and cultures converge," said Prof. Takao Hensch, Director of the International Research Center for Neurointelligence, Professor of Molecular and Cellular Biology at the Harvard Center for Brain Science, and Professor of Neurology at Harvard Medical School. "By infusing science and entrepreneurship with the spirit of collaboration, we hope to inspire a new generation of leaders who will transform their curiosity into real-world impact. Together with Corundum, we are cultivating a community where the next big ideas in neurotech innovation can flourish." A highlight of the workshop will be an immersive session led by a team from Harvard University's Lemann Program on Creativity and Entrepreneurship (LPCE), focused on venture storytelling and pitch readiness. The session will emphasize both cross-disciplinary and cross-generational collaboration, particularly the integration of the liberal arts with sciences and entrepreneurship, which aligns with the vision of CCI and IRCN. LPCE is also actively engaged in building international communities outside of its Boston base, making Japan a future site for this growing global network of researchers, innovators and entrepreneurs. About Corundum Convergence Institute Corundum Convergence Institute (CCI) is a non-profit organization committed to advancing transformative research at the frontiers of neuroscience, systems biology, and artificial intelligence. By focusing on early-stage innovation in complex, high-impact fields, CCI supports the development of products and technologies leading to paradigm shifts in healthcare, including novel therapeutic approaches to neuro-inspired AI and improved diagnostics for neurodegenerative and metabolic conditions. CCI's multidisciplinary approach fosters convergence across fields, enabling scientists and entrepreneurs to explore the intersections of science, human biology and advanced technology in ways that will fundamentally reshape health and wellbeing. CCI is an independently governed entity created by fellow Corundum Corp venture builders and funds Corundum Neuroscience and Corundum Systems Biology. As part of the greater Corundum network, CCI offers a creative path to translate bold scientific ideas to real-world impact. For company updates and information, follow Corundum Convergence Institute on LinkedIn or visit Media Contact: Danny SudwartsFINN Partners for View original content: SOURCE Corundum Convergence Institute
